Q3 2025 Earnings Estimate for Halozyme Therapeutics, Inc. Issued By Zacks Research (NASDAQ:HALO)

Halozyme Therapeutics, Inc. (NASDAQ:HALO) – Analysts at Zacks Research upped their Q3 2025 earnings per share estimates for shares of Halozyme Therapeutics in a research note issued to investors on Monday, April 22nd. Zacks Research analyst A. Chakraborty now anticipates that the biopharmaceutical company will post earnings of $1.01 per share for the quarter, up from their previous estimate of $0.98. The consensus estimate for Halozyme Therapeutics’ current full-year earnings is $3.45 per share. Zacks Research also issued estimates for Halozyme Therapeutics’ FY2025 earnings at $3.92 EPS and Q1 2026 earnings at $1.21 EPS.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Tuesday, February 20th. The biopharmaceutical company reported $0.75 EPS for the quarter, missing the consensus estimate of $0.77 by ($0.02). Halozyme Therapeutics had a return on equity of 248.20% and a net margin of 33.96%. The business had revenue of $230.04 million for the quarter, compared to the consensus estimate of $235.25 million.

Several other analysts also recently issued reports on the company. JMP Securities restated a “market outperform” rating and issued a $72.00 price target on shares of Halozyme Therapeutics in a research note on Wednesday, February 21st. TheStreet downgraded Halozyme Therapeutics from a “b-” rating to a “c+” rating in a research note on Monday, January 22nd. TD Cowen began coverage on Halozyme Therapeutics in a research note on Thursday, February 29th. They issued an “outperform” rating and a $54.00 price target for the company. Benchmark restated a “buy” rating and issued a $50.00 price target on shares of Halozyme Therapeutics in a research note on Tuesday, April 16th. Finally, StockNews.com upgraded Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, February 23rd. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $53.29.

Halozyme Therapeutics Stock Performance

Shares of NASDAQ HALO opened at $38.97 on Tuesday. The stock has a 50 day moving average of $39.62 and a 200-day moving average of $37.78. The company has a market capitalization of $4.95 billion, a P/E ratio of 18.48, a P/E/G ratio of 0.45 and a beta of 1.25. Halozyme Therapeutics has a 12 month low of $29.85 and a 12 month high of $45.00. The company has a current ratio of 6.64, a quick ratio of 5.50 and a debt-to-equity ratio of 17.89.

Insider Transactions at Halozyme Therapeutics

In other news, SVP Michael J. Labarre sold 10,000 shares of the business’s stock in a transaction on Wednesday, April 17th. The stock was sold at an average price of $38.49, for a total transaction of $384,900.00. Following the completion of the transaction, the senior vice president now owns 168,176 shares of the company’s stock, valued at approximately $6,473,094.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In the last quarter, insiders sold 30,000 shares of company stock valued at $1,196,800. Corporate insiders own 2.70% of the company’s stock.

Hedge Funds Weigh In On Halozyme Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of HALO. Vontobel Holding Ltd. acquired a new position in Halozyme Therapeutics in the 3rd quarter worth about $249,000. Exchange Traded Concepts LLC increased its holdings in Halozyme Therapeutics by 16.2% in the 3rd quarter. Exchange Traded Concepts LLC now owns 14,129 shares of the biopharmaceutical company’s stock worth $540,000 after purchasing an additional 1,974 shares in the last quarter. Handelsbanken Fonder AB increased its holdings in Halozyme Therapeutics by 8.2% in the 3rd quarter. Handelsbanken Fonder AB now owns 23,869 shares of the biopharmaceutical company’s stock worth $912,000 after purchasing an additional 1,800 shares in the last quarter. Linden Thomas Advisory Services LLC increased its holdings in Halozyme Therapeutics by 13.7% in the 3rd quarter. Linden Thomas Advisory Services LLC now owns 42,450 shares of the biopharmaceutical company’s stock worth $1,622,000 after purchasing an additional 5,126 shares in the last quarter. Finally, Commonwealth Equity Services LLC increased its holdings in Halozyme Therapeutics by 2.2% in the 3rd quarter. Commonwealth Equity Services LLC now owns 16,216 shares of the biopharmaceutical company’s stock worth $619,000 after purchasing an additional 347 shares in the last quarter. Institutional investors and hedge funds own 97.79% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.